Published in PLoS One on March 24, 2017
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 4.60
Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology (2015) 3.04
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer (2012) 2.10
Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore) (2015) 1.88
Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg (2015) 1.33
Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg (2012) 1.33
A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis (2008) 1.32
Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther (2003) 1.25
Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother (2008) 1.22
Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. Hepatol Res (2010) 1.21
Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev (2009) 1.20
Postoperative therapy options for hepatocellular carcinoma. Scand J Gastroenterol (2014) 1.15
The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol (2013) 1.07
Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol (2012) 1.07
Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol (2010) 1.04
Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut (2015) 1.02
Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann Surg Oncol (2014) 1.01
Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med (2013) 1.01
Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract (2012) 1.00
Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Chin J Cancer (2010) 1.00
Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. Chin J Cancer (2010) 0.97
Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol (2010) 0.97
Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother (2013) 0.96
An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol (2011) 0.96
Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One (2012) 0.95
Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer (2015) 0.91
Current status of adoptive immunotherapy of malignancies. Expert Opin Biol Ther (2002) 0.91
Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget (2015) 0.90
A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol (2013) 0.89
Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol (1995) 0.88
Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. PLoS One (2013) 0.87
[Dendritic cell-cytokine induced killer cell immunotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: safety and efficacy]. Nan Fang Yi Ke Da Xue Xue Bao (2014) 0.84
Postoperative hepatitis B virus reactivation and surgery-induced immunosuppression in patients with hepatitis B-related hepatocellular carcinoma. J Surg Oncol (2015) 0.82
[Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma]. Ai Zheng (2006) 0.82
A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology (2015) 0.81
A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Sci Rep (2015) 0.81
Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma. Hepatogastroenterology (2006) 0.81
Combinatorial immunotherapy strategies for hepatocellular carcinoma. Curr Opin Immunol (2016) 0.81
[The effects of combined hepatectomy and immuno-chemotherapy on postoperative recurrence rate of primary liver cancer]. Zhonghua Wai Ke Za Zhi (1995) 0.80
Effects of hepatic artery chemotherapeutic embolization combined with perfusing LAK cells into hepatic artery after radical operation of liver cancer. Zhonghua Gan Zang Bing Za Zhi (2000) 0.80
Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma. JAMA Surg (2017) 0.78
High leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patients. Oncotarget (2016) 0.78
Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection. Medicine (Baltimore) (2016) 0.77
Prevention of hepatocellular carcinoma recurrence: actuality and perspectives. Hepatogastroenterology (2002) 0.77
Postoperative chemoimmunotherapy for the treatment of liver cancer. Semin Surg Oncol (1993) 0.77
Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review. Oncotarget (2017) 0.77
PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology (2016) 0.76
Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients. PLoS One (2016) 0.76
Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model. Cancer Biol Ther (2017) 0.76
Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer (2015) 0.78
Hepatic resection is superior to transarterial chemoembolization for treating intermediate-stage hepatocellular carcinoma. Liver Int (2016) 0.78
Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget (2017) 0.76
Reply. Hepatology (2015) 0.75
Extrahepatic metastasectomy for hepatocellular carcinoma: Predictors of long-term survival. J Surg Oncol (2017) 0.75
Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. Oncotarget (2017) 0.75
Successful Dual Kidney Transplantation After Hypothermic Oxygenated Perfusion of Discarded Human Kidneys. Am J Case Rep (2017) 0.75
Transarterial embolization for hepatocellular adenomas: a literature review. Oncotarget (2017) 0.75
Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. Oncotarget (2017) 0.75